Year All202320222021 KemPharm to Report Third Quarter 2022 Financial Results 11-01-2022 KemPharm Supports Niemann-Pick Awareness Month During October and Global Niemann-Pick Awareness Day on October 19th 10-04-2022 KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX) 09-28-2022 KemPharm to Present at the H.C. Wainwright 24th Annual Global Investment Conference 09-01-2022 KemPharm Reports Second Quarter 2022 Financial Results and Corporate Updates 08-11-2022 KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications 08-09-2022 KemPharm to Report Second Quarter 2022 Financial Results 08-04-2022 KemPharm to Present at the Canaccord Genuity 42nd Annual Growth Conference 08-02-2022 KemPharm to Participate in the 2022 Joint NNPDF-INPDA Conference and Meeting 07-26-2022 KemPharm Announces Research Affirming Serdexmethylphenidate’s Lower Potential for Abuse Featured in Peer-Reviewed Publication, Current Medical Research & Opinion 06-01-2022
KemPharm Supports Niemann-Pick Awareness Month During October and Global Niemann-Pick Awareness Day on October 19th 10-04-2022
KemPharm Announces Positive Topline Data from Phase 1 Clinical Trial Evaluating Cardiovascular Safety of Serdexmethylphenidate (SDX) 09-28-2022
KemPharm Appoints Nichol Ochsner as Vice President, Investor Relations and Corporate Communications 08-09-2022
KemPharm Announces Research Affirming Serdexmethylphenidate’s Lower Potential for Abuse Featured in Peer-Reviewed Publication, Current Medical Research & Opinion 06-01-2022
